Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
The Autologous Stem Cell Transplant is the standard-of-care for newly diagnosis multiple myeloma patients as well as for other blood cancers. ASCT is high-dose multiple myeloma chemotherapy. ASCT are given to the majority of MM patients to achieve the longest possible overall survival (OS).
The study linked and excerpted below was authored, in part, by the oncologist who managed my autologous stem cell transplant- Hillard Lazarus M.D. The article below was published in 2014.
I had my ASCT in December of 1995. Dr. Lazarus had 19 years from my ASCT to the publication of the study below to learn about ASCT in MMers.
What is known about autologous stem cell transplantation for multiple myeloma patients and survivors?
I’m not a board certified oncologist. I’m just a long-term MM survivor who’s learned a lot about multiple myeloma chemotherapy and cancer survival through research and personal experience.
Multiple myeloma chemotherapy and radiation are toxic. Though it may be necessary for MMers at times, the less toxicity the better. “Less is more” as far as I’m concerned. Its that simple. Less is more in MM.
Are you considering an autologous stem cell transplant for your MM? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT) typically receive a finite period of initial therapy before ASCT. It is not clear if patients with suboptimal (less than a partial) response to initial therapy benefit from additional alternative therapy with intent to maximize pretransplant response.
We identified 539 patients with MM who had an ASCT after having achieved less than a partial response (PR) to first-line induction chemotherapy between 1995 and 2010.
These patients were then divided into 2 groups:
Additional pretransplant chemotherapy resulted in deepening responses in 68% (complete response in 8% and PR in 60%).
On multivariate analysis there was no impact of pretransplant salvage chemotherapy on
In conclusion, for patients achieving less than a PR to initial induction therapy, including with novel agent combinations, additional pre-ASCT salvage chemotherapy improved the depth of response and pre-ASCT disease status but was not associated with survival benefit.”